The National Medical Products Administration of China has approved toripalimab combined with axitinib (Inlyta) for use in the first-line treatment of patients with medium- to high-risk unresectable or metastatic renal cell carcinoma (RCC)
Inlyta is indicated for the treatment of adult patients with advanced renal cell carcinoma (RCC) after failure of prior treatment with sunitinib or a cytokine.
AVEO Oncology has announced that the first patient has been dosed in the Company’s pivotal TIVO-3 trial, a randomized, controlled,...
A Phase III study AGILE 1051, of Inlyta (axitinib) from Pfizer, did not meet its primary endpoint of demonstrating statistically...
Merck Inc., announced that the FDA has approved Keytruda, Merck’s anti-PD-1 therapy, in combination with Inlyta (axitinib), a tyrosine kinase...
Shanghai Junshi Biosciences announced that the pre-specified interim analysis of the RENOTORCH study (NCT04394975) has been completed
Merck and Pfizer Inc. announced that the FDA has approved Bavencio (avelumab) in combination with axitinib for the first-line treatment...